Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of October 2017, with the report dated October 3, 2017. The filing serves as a notification regarding the expiration timeline for Series 5 tradable options issued by the Company and traded exclusively on the Tel Aviv Stock Exchange (TASE).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses solely on corporate action regarding equity instruments.
- Instrument: Series 5 Tradable Options (Ticker: BVXV.W5, ISIN: IL0011304008).
- Exercise Price: NIS 1.50 per option (approximately $0.423 USD based on the October 2, 2017 exchange rate of 3.542 NIS = $1.00).
- Trading Venue: Tel Aviv Stock Exchange (TASE) only; not listed on the NASDAQ Capital Market.
Material Changes
The filing announces specific deadlines for the Series 5 options:
- Last Trade Day on TASE: October 24, 2017.
- Final Exercise Deadline: October 29, 2017.
- Consequence of Inaction: Options not exercised by the deadline will expire and grant no rights to holders.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management commentary on future operations, or discussion of general business risks. The primary contingency noted is the total loss of value for Series 5 option holders who fail to exercise their rights by October 29, 2017.
Investor Verification Checklist
- Verify the current status of Series 5 options (BVXV.W5) on the Tel Aviv Stock Exchange.
- Confirm the exchange rate used for the USD conversion of the exercise price if holding foreign currency.
- Ensure awareness that these options are not tradable on U.S. exchanges (NASDAQ).
- Note that this filing does not contain financial performance data for the period.